Draft medication scaffold. Needs source pass before publish.
Sections
Isocarboxazid is one of the old MAOIs, which means it lives in that strange category of medications that can work extremely well and also make everybody in the room a little tense. Marplan isn’t a first-choice antidepressant, and the label says that plainly, but the reason it still matters is that some people really do respond to MAOIs in a way they don’t respond to safer, cleaner, more ordinary modern options.
The catch is obvious and it isn’t small: dietary restrictions, frightening drug interactions, blood-pressure crisis risk, serotonin-toxicity risk with the wrong combinations, and the general fact that this isn’t a casual medication for a casual prescriber. When people romanticize MAOIs as hidden gems, I think they usually underplay how much discipline they demand from both doctor and patient.
What it actually does
Isocarboxazid is a nonselective irreversible monoamine oxidase inhibitor. In plain language, it raises monoamine signaling by blocking the enzyme that breaks those neurotransmitters down, and it does that broadly enough that food interactions and medication interactions become a central part of the treatment story, not some side note you mention at the end.
That mechanism is part of why it can help in otherwise difficult depression, especially where anxiety or so-called atypical features are mixed in, but it’s also why the drug has so many rules attached to it. With MAOIs, the pharmacology and the lifestyle instructions are really the same conversation.
Where it tends to help most
Depression is the official indication, and the label cites placebo-controlled outpatient studies showing benefit. In real life, MAOIs tend to matter most when the depression hasn’t responded well to more standard options, or when the clinical picture has that anxious, atypical, reactive quality where this class has always had a reputation for doing better than people expect.
When it makes sense and when it doesn’t
I like isocarboxazid when depression has been stubborn, when the patient understands exactly what kind of medication this is, and when both sides are actually willing to do the careful work that MAOI treatment requires. In that setting, it can be a very real option and sometimes a very good one.
I don’t love it in patients who are chaotic with medications, in people who are unlikely to respect the food and interaction rules, in anyone with the contraindicated medical issues from the label, or in situations where safer options haven’t really been given a fair shot yet. You should have a reason to climb this mountain.
- What symptom or function is supposed to change, not just whether the medication feels noticeable.
- Sleep, appetite, libido, mood, anxiety, blood pressure, sedation, and any side effect that changes the trade.
- Missed doses, alcohol, cannabis, and other meds, because those can make a clean read impossible.
The useful question with Isocarboxazid (Marplan) is not whether it sounds strong or old or scary. The useful question is whether the benefit is real enough to justify the trade.
The patient-autonomy part
If somebody hears the whole trade and still wants to try an MAOI because the depression has been bad enough and the standard playbook hasn’t done the job, that’s a serious but completely legitimate decision. Adults are allowed to choose treatments that demand more from them if the potential upside is worth it.
If they hear the same trade and decide the diet, interaction burden, and overall vigilance sound like too much, that’s also legitimate. A medication isn’t automatically better just because it’s older, rarer, or more hardcore.
What to know before stopping or switching
Stopping or switching an MAOI isn’t casual. Washout periods matter. What you switch to next matters. Hidden serotonergic overlap matters. This is a drug where being sloppy for even a week can create avoidable danger.
If you’re going to use isocarboxazid at all, you really do have to treat the rules as part of the medication and not as extra paperwork around it.
Bottom line
Isocarboxazid is an older MAOI that is still relevant because some depressions respond to this class in a way they don’t respond to easier medications. Its advantage is real potential efficacy in difficult depression. Its downside is that the food restrictions, interaction hazards, and blood-pressure risk make it one of the least casual antidepressants in psychiatry. It’s a serious tool for serious use.
Sources
- DailyMed. MARPLAN isocarboxazid tablet. National Library of Medicine. Accessed June 6, 2026. Official label.
- Riley VE, Stewart DE. Isocarboxazid. Efficacy and tolerance. Can J Psychiatry. 1983;28(7):575-578. PMID 6222098.
- Quitkin FM, Stewart JW, McGrath PJ, et al. Monoamine oxidase inhibitor-responsive depression. J Clin Psychopharmacol. 1988;8(4 Suppl):31S-35S. PMID 7036196.
